Altmetric – Effect of rosuvastatin on outcomes in chronic haemodialysis patients

You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Title	Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study
Published in	Current Controlled Trials in Cardiovascular Medicine, May 2005
DOI	10.1186/1468-6708-6-9
Pubmed ID	15910680
Authors	Bengt Fellström, Faiez Zannad, Roland Schmieder, Hallvard Holdaas, Alan Jardine, Helen Rose, Wim Wilpshaar
Abstract	Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk of cardiovascular mortality in this population. In contrast to patients with normal renal function, the benefits of modifying lipid levels on cardiovascular outcomes in patients with ESRD on haemodialysis have yet to be confirmed in large prospective randomised trials. A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA) will be the first large-scale international trial to assess the effects of statin therapy on cardiovascular morbidity and mortality in ESRD patients on chronic haemodialysis.

View on publisher site Alert me about new mentions

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
Unknown	38	100%

Demographic breakdown

Readers by professional status	Count	As %
Student > Ph. D. Student	4	11%
Researcher	4	11%
Student > Postgraduate	4	11%
Professor	3	8%
Student > Bachelor	3	8%
Other	10	26%
Unknown	10	26%

Readers by discipline	Count	As %
Medicine and Dentistry	17	45%
Business, Management and Accounting	2	5%
Pharmacology, Toxicology and Pharmaceutical Science	2	5%
Biochemistry, Genetics and Molecular Biology	1	3%
Nursing and Health Professions	1	3%
Other	4	11%
Unknown	11	29%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2010.

All research outputs

#7,454,427

of 22,789,566 outputs

Outputs from Current Controlled Trials in Cardiovascular Medicine

#13

of 26 outputs

Outputs of similar age

#20,349

of 57,636 outputs

Outputs of similar age from Current Controlled Trials in Cardiovascular Medicine

of 2 outputs

Altmetric has tracked 22,789,566 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.

So far Altmetric has tracked 26 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.5. This one scored the same or higher as 13 of them.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 57,636 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.

We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them

Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study

Mentioned by

Citations

Readers on

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context